search
Back to results

The CHECK Trial: A Comparison of Headache Treatment in the Emergency Department: Compazine Versus Ketamine (Check)

Primary Purpose

Headache

Status
Terminated
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Compazine
Ketamine
Sponsored by
Mike O'Callaghan Military Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Headache

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

THIS STUDY IS BEING CONDUCTED AT A MILITARY INSTALLATION. YOU MUST HAVE MILITARY INSURANCE IN ORDER TO PARTICIPATE IN THIS STUDY.

Inclusion Criteria

  • Age 18 to 65 years who present to the ED with complaint of a headache
  • Temperature less than 100.4 F
  • Diastolic blood pressure less than 104 mm Hg
  • Normal neurologic exam and normal mental status

Exclusion Criteria

  • Pregnant or breastfeeding
  • Meningeal signs are present
  • Acute angle closure glaucoma is suspected
  • Head trauma within the previous two weeks
  • Lumbar puncture within the previous two weeks
  • Thunderclap (rapid) onset of the headache
  • Weight more than 150 kg or less than 40 kg
  • Known allergy to diphenhydramine
  • Known allergy to ondansetron. (Zofran)
  • Known allergy to Compazine
  • Known allergy to Ketamine
  • History of schizophrenia or bipolar disorder
  • History of intracranial hypertension
  • Is a prisoner
  • Patient declined informed consent
  • Non-English speaking patient
  • Attending provider excludes patient
  • Elderly patients with dementia
  • Patients with severe headaches that diminish their decision making capability will not be able to participate

Sites / Locations

  • Mike O'Callaghan Federal Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Standard treatment arm

Research arm

Arm Description

compazine 10 mg Intravenously along with diphenhydramine 25 mg Intravenously

Ketamine 0.3 mg/kg Intravenously along with ondansetron 4 mg Intravenously

Outcomes

Primary Outcome Measures

Pain Score

Secondary Outcome Measures

Full Information

First Posted
March 31, 2016
Last Updated
May 31, 2017
Sponsor
Mike O'Callaghan Military Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT02735343
Brief Title
The CHECK Trial: A Comparison of Headache Treatment in the Emergency Department: Compazine Versus Ketamine
Acronym
Check
Official Title
The CHECK Trial: A Comparison of Headache Treatment in the Emergency Department: Compazine Versus Ketamine. A Multi-Center, Randomized, Double-Blind, Clinical Control Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2017
Overall Recruitment Status
Terminated
Why Stopped
only recruited 5 patients at this location
Study Start Date
August 2016 (Actual)
Primary Completion Date
May 2017 (Actual)
Study Completion Date
May 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mike O'Callaghan Military Hospital

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Investigators are comparing Ketamine to prochlorperazinecompazine for benign headaches in the ED. Subjects will be randomized into 1 of 2 groups. Group 1 will receive standard treatment of prochlorperazinecompazine 10 mg IV along with diphenhydramine 25 mg IV. Group 2 (research arm) will receive Ketamine 0.3 mg/kg along with ondansetron 4 mg IV. Subjects will be seen at 15, 30, 45, and 60 minutes post-intervention to obtain Heart Rate, Blood Pressure, Headache severity, Nausea severity, Vomiting severity, Anxiety severity, and Restlessness severity. At 24-48 hours post intervention we will contact subjects and assess their pain and assess their satisfaction with their migraine pain management as part of this study. Subjects' participation will last up to 48 hours post headache.
Detailed Description
Screening Visit: Obtain signed Informed Consent Document and HIPAA Authorization (research-driven). Record: Date of birth, age, phone number, gender, race, ethnicity, social security number, name of standard of care rescue medications (over-the-counter and prescription), current email address (to be used for scheduling only), height (in inches), weight (in pounds), history of traumatic brain injury, concussion, or any mild to severe head trauma, medication use. (research only) Review past medical history in Armed Forces Health Longitudinal Technology Application (AHLTA) or ESSENTRIS to verify the inclusion/exclusion criteria. Women of childbearing potential will have a serum pregnancy test (5-10 milliliters (mls), approximately 1-2 teaspoons of blood) (research-driven). Visit 1: Heart rate Blood pressure Headache severity via 100-mm VAS. Nausea severity via 100-mm VAS. Vomiting severity via 100-mm VAS. Anxiety severity via 100-mm VAS. Restlessness severity via 100-mm VAS. Record type and amount of rescue medications (over-the-counter and prescription) use in the past 7 days. (research only) Subjects will be randomized by the pharmacy. We will use a random-number generator and use blocking to ensure roughly equal sample sizes. Both subjects and investigators will be blinded to the study group assignments. Subjects will be randomized by the pharmacy into one of two groups (research-driven): Group 1: Standard treatment arm (prochlorperazinecompazine 10 mg IV along with diphenhydramine 25 mg IV) Group 2: Research arm (Ketamine 0.3 mg/kg along with ondansetron 4 mg IV) 15 minutes post treatment: Heart rate Blood pressure Headache severity via 100-mm VAS. Nausea severity via 100-mm VAS. Vomiting severity via 100-mm VAS. Anxiety severity via 100-mm VAS. Restlessness severity via 100-mm VAS. 30 minutes post treatment: Heart rate Blood pressure Headache severity via 100-mm VAS. Nausea severity via 100-mm VAS. Vomiting severity via 100-mm VAS. Anxiety severity via 100-mm VAS. Restlessness severity via 100-mm VAS. 45 minutes post treatment: Heart rate Blood pressure Headache severity via 100-mm VAS. Nausea severity via 100-mm VAS. Vomiting severity via 100-mm VAS. Anxiety severity via 100-mm VAS. Restlessness severity via 100-mm VAS. 60 minutes post treatment: Heart rate Blood pressure Headache severity via 100-mm VAS. Nausea severity via 100-mm VAS. Vomiting severity via 100-mm VAS. Anxiety severity via 100-mm VAS. Restlessness severity via 100-mm VAS. 24-48 hours post treatment: Subjects will be contacted either in-person or via phone and the following information will be collected: Subjects will be asked "On a scale of 0-10, with 10 being the worst pain, what is your current level of pain?" Subjects will be asked "On a scale of 0 to 10, how satisfied were you with you're the migraine pain management as part of this research study? (dissatisfied 0 - 10 very satisfied) Subjects will be alerted to what group they were randomized into.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Headache

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
5 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Standard treatment arm
Arm Type
Active Comparator
Arm Description
compazine 10 mg Intravenously along with diphenhydramine 25 mg Intravenously
Arm Title
Research arm
Arm Type
Experimental
Arm Description
Ketamine 0.3 mg/kg Intravenously along with ondansetron 4 mg Intravenously
Intervention Type
Drug
Intervention Name(s)
Compazine
Other Intervention Name(s)
prochlorperazine
Intervention Description
Compazine 10mg with diphenhydramine 25 mg IV
Intervention Type
Drug
Intervention Name(s)
Ketamine
Intervention Description
Ketamine 0.3 mg/kg along with ondansetron 4 mg IV
Primary Outcome Measure Information:
Title
Pain Score
Time Frame
60 minutes

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
THIS STUDY IS BEING CONDUCTED AT A MILITARY INSTALLATION. YOU MUST HAVE MILITARY INSURANCE IN ORDER TO PARTICIPATE IN THIS STUDY. Inclusion Criteria Age 18 to 65 years who present to the ED with complaint of a headache Temperature less than 100.4 F Diastolic blood pressure less than 104 mm Hg Normal neurologic exam and normal mental status Exclusion Criteria Pregnant or breastfeeding Meningeal signs are present Acute angle closure glaucoma is suspected Head trauma within the previous two weeks Lumbar puncture within the previous two weeks Thunderclap (rapid) onset of the headache Weight more than 150 kg or less than 40 kg Known allergy to diphenhydramine Known allergy to ondansetron. (Zofran) Known allergy to Compazine Known allergy to Ketamine History of schizophrenia or bipolar disorder History of intracranial hypertension Is a prisoner Patient declined informed consent Non-English speaking patient Attending provider excludes patient Elderly patients with dementia Patients with severe headaches that diminish their decision making capability will not be able to participate
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christopher Pitotti, MD
Organizational Affiliation
Mike O'Callaghan Federal Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mike O'Callaghan Federal Medical Center
City
Nellis Air Force Base
State/Province
Nevada
ZIP/Postal Code
89191
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
De-identified data will be shared with University Medical Center of Southern Nevada via a Cooperative Research and Development Agreement. They are conducing the same study under a different IRB.
Citations:
PubMed Identifier
29089172
Citation
Driver BE, Klein LR, Carlson K, Harrington J, Reardon RF, Prekker ME. Preoxygenation With Flush Rate Oxygen: Comparing the Nonrebreather Mask With the Bag-Valve Mask. Ann Emerg Med. 2018 Mar;71(3):381-386. doi: 10.1016/j.annemergmed.2017.09.017. Epub 2017 Oct 28.
Results Reference
derived
PubMed Identifier
29033296
Citation
Zitek T, Gates M, Pitotti C, Bartlett A, Patel J, Rahbar A, Forred W, Sontgerath JS, Clark JM. A Comparison of Headache Treatment in the Emergency Department: Prochlorperazine Versus Ketamine. Ann Emerg Med. 2018 Mar;71(3):369-377.e1. doi: 10.1016/j.annemergmed.2017.08.063. Epub 2017 Oct 14.
Results Reference
derived

Learn more about this trial

The CHECK Trial: A Comparison of Headache Treatment in the Emergency Department: Compazine Versus Ketamine

We'll reach out to this number within 24 hrs